Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ZSP1603 in Healthy Chinese Subjects
NCT03619616Phase 1Completed
- Sponsor
- Zhongsheng Pharma
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZSP1603 in idiopathic pulmonary fibrosis (IPF) and solid tumor (4 arms), sponsored by Zhongsheng Pharma. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Jul 2018; status: completed.
02
Drugs
ZSP1603
03
Conditions
idiopathic pulmonary fibrosis (IPF)solid tumor
Beyond the preview
Go deeper on NCT03619616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619616.